Host cell factors as antiviral targets in arenavirus infection

Viruses

Volumn 4, Issue 9, 2012, Pages 1569-1591

  Linero, Florencia N ^a   Sepúlveda, Claudia S ^a   Giovannoni, Federico ^a   Castilla, Viviana ^a   García, Cybele C ^a   Scolaro, Luis A ^a   Damonte, Elsa B ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Antiviral; Arenavirus; Hemorrhagic fever; Host cell target; Junin virus

Indexed keywords

CELL PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HOST FACTOR; INTERFERON; NUCLEOSIDE; PHOSPHOTRANSFERASE;

ARENAVIRUS INFECTION; DOWN REGULATION; HOST CELL; HUMAN; IMMUNE RESPONSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; RNA PROCESSING; RNA SYNTHESIS; TARGET CELL; UPREGULATION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; ARENAVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS;

ARENAVIRIDAE; ARENAVIRUS; JUNIN VIRUS; LASSA VIRUS; RNA VIRUSES;

EID: 84867025801     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4091569     Document Type: Review

References (146)

1. McCormick, J.B.; Fisher-Hoch, S.P. Lassa fever. Curr. Top. Microbiol. Immunol. 2002, 262, 75-109.
2. Enria, D.A.; Briggiler, A.M.; Sánchez, Z. Treatment of Argentine hemorrhagic fever. Antivir. Res. 2008, 78, 132-139.
3. Macher, A.M.; Wolfe, M.S. Historical Lassa fever reports and 30-year clinical update. Emerg. Infect. Dis. 2006, 12, 835-836.
4. Jamieson, D.J.; Kourtis, A.P.; Bell, M.; Rasmussen, S.A. Lymphocytic choriomeningitis virus: An emerging obstetric pathogen? Am. J. Obstet. Gynecol. 2006, 194, 1532-1536.
5. Fisher, S.A.; Graham, M.B.; Kuehnert, M.J.; Kotton, C.N.; Srinivasan, A.; Marty, F.M.; Comer, J.A.; Guarner, J.; Paddock, C.D.; DeMeo, D.L.; et al. LCMV in Transplant recipients investigation team. Transmission of lymphocytic choriomeningiris virus by organ transplantation. N. Engl. J. Med. 2006, 354, 2235-2249.
6. Charrel, R.N.; de Lamballerie, X. Zoonotic aspects of arenavirus infections. Vet. Microbiol. 2010, 140, 213-220.
7. McCormick, J.B.; King, I.J.; Webb, P.A.; Scribner, C.L.; Craven, R.B.; Johnson, K.M.; Elliot, L.H.; Belmont-Williams, R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20-26.
8. Peters, C.J. Human infection with arenaviruses in the Americas. Curr. Top. Microbiol. Immunol. 2002, 262, 65-74.
9. Fisher-Hoch, S.P.; Ghorie, S.; Parker, L.; Huggins, J. Unexpected adverse reactions during a clinical trial in rural West Africa. Antivir. Res. 1992, 19, 139-147.
10. Enria, D.A.; Maiztegui, J.I. Antiviral treatment of Argentine hemorrhagic fever. Antivir. Res. 1994, 23, 23-31.
11. Duffy, S.; Shackelton, L.A.; Holmes, E.C. Rates of evolutionary change in viruses: Patterns and determinants. Nat. Rev. Genet. 2008, 9, 257-276.
12. Sanjuán, R.; Nebot, M.R.; Chirico, N.; Mansky, L.M.; Belshaw, R. Viral mutation rates. J. Virol. 2010, 84, 9733-9748.
13. Coley, W.; Kehn-Hall, K.; van Duyne, R.; Kashanchi, F. Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin. Biol. Ther. 2009, 9, 1369-1382.
14. Khattab, M.A. Targeting host factors: A novel rationale for the management of hepatitis C virus. World J. Gastroenterol. 2009, 15, 3472-3479.
15. Krumm, S.A.; Ndungu, J.M.; Yoon, J.J.; Dochow, M.; Sun, A.; Natchus, M.; Snyder, J.P.; Plemper, R.K. Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One 2011, 6, e20069.
16. Pastorino, B.; Nougairede, A.; Wurtz, N.; Gould, E.; de Lamballerie, X. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs. Antivir. Res. 2010, 87, 281-294.
17. Albariño, C.G.; Bergeron, E.; Erickson, B.R.; Khristova, M.L.; Rollin, P.E.; Nichol, S.T. Efficient reverse genetics generation of infectious junin viruses differing in glycoprotein processing. J. Virol. 2009, 83, 5606-5614.
18. Emonet, S.F.; Seregin, A.V.; Yun, N.E.; Poussard, A.L.; Walker, A.G.; de la Torre, J.C.; Paessler, S. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J. Virol. 2011, 85, 1473-1483.
19. Carnec, X.; Baize, S.; Reynard, S.; Diancourt, L.; Caro, V.; Tordo, N.; Bouloy, M. Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J. Virol. 2011, 85, 12093-12097.
20. Larson, R.A.; Dai, D.; Hosack, V.T.; Tan, Y.; Bolken, T.C.; Hruby, D.E.; Amberg, S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 2008, 82, 10768-10775.
21. Lee, A.M.; Rojek, J.M.; Spiropoulou, C.F.; Gundersen, A.T.; Jin, W.; Shaginian, A.; York, J.; Nunberg, J.H.; Boger, D.L.; Oldstone, M.B.; et al. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 2008, 283, 18734-18742.
22. Capul, A.A.; de la Torre, J.C. A cell-based luciferase assay amenable to high-throughput screening of arenavirus budding. Virology 2008, 382, 107-114.
23. Friedel, C.C.; Jurgen, H. Virus-Host interactomes and global models of virus-infected cells. Trends Microbiol. 2011, 19, 501-508.
24. Shaw, M.L. The host interactome of influenza virus presents new potential targets for antiviral drugs. Res. Med. Virol. 2011, 21, 358-369.
25. Tafforeau, L.; Rabourdin-Combe, C.; Lotteau, V. Virus-Human cell interactomes. Methods Mol. Biol. 2012, 812, 103-120.
26. Djavani, M.; Crasta, O.R.; Zhang, Y.; Zapata, J.C.; Sobral, B.; Lechner, M.G.; Bryant, J.; Davis, H.; Salvato, M.S. Gene expression in primate liver during viral hemorrhagic fever. Virol. J. 2009, 6, 20:1-20:18.
27. Müller, S.; Geffers, R.; Günther, S. Analysis of gene expression in Lassa virus-infected HuH-7 cells. J. Gen. Virol. 2007, 88, 1568-1575.
28. Bowick, G.C.; Fennewald, S.M.; Elsom, B.L.; Aronson, J.F.; Luxon, B.A.; Gorenstein, D.G.; Herzog, N.K. Differential signaling networks induced by mild and lethal hemorrhagic fever virus infections. J. Virol. 2006, 80, 10248-10252.
29. Bowick, G.C.; Fennewald, S.M.; Scott, E.P.; Zhang, L.; Elsom, B.L.; Aronson, J.F.; Spratt, H.M.; Luxon, B.A.; Gorenstein, D.G.; Herzog, N.K. Identification of differentially activated cell-signaling networks associated with Pichinde virus pathogenesis by using systems kinomics. J. Virol. 2007, 81, 1923-1933.
30. García, C.C.; Sepúlveda, C.S.; Damonte, E.B. Novel therapeutic targets for arenavirus hemorrhagic fevers. Future Virol. 2011, 6, 27-44.
31. Emonet, S.E.; Urata, S.; de la Torre, J.C. Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 2011, 411, 416-425.
32. Lee, A.M.; Pasquato, A.; Kunz, S. Novel approaches in anti-arenaviral drug development. Virology 2011, 411, 163-169.
33. Rojek, J.M.; Kunz, S. Cell entry by human pathogenic arenaviruses. Cell. Microbiol. 2008, 10, 828-835.
34. Streeter, D.G.; Witkowski, J.T.; Khare, G.P.; Sidwell, R.W.; Bauer, R.J.; Robins, R.K.; Simon, L.N. Mechanism of action of 1-ß-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 1973, 70, 1174-1178.
35. Leyssen, P.; Balzarini, J.; de Clercq, E.; Neyts, J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 2005, 79, 1943-1947.
36. Graci, J.D.; Cameron, C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006, 16, 37-48.
37. Leyssen, P.; de Clercq, E.; Neyts, J. Molecular strategies to inhibit the replication of RNA viruses. Antivir. Res. 2008, 78, 9-25.
38. Ölschläger, S.; Neyts, J.; Günther, S. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antivir. Res. 2011, 91, 89-93.
39. Sepúlveda, C.S.; García, C.C.; Fascio, M.L.; D'Accorso, N.B.; Docampo Palacios, M.L.; Pellón R, F.; Damonte, E.B. Inhibition of Junín virus RNA synthesis by an antiviral acridone derivative. Antivir. Res. 2012, 96, 16-22.
40. Ruiz-Jarabo, C.M.; Ly, C.; Domingo, E.; de la Torre, J.C. Lethal mutagenesis of the prototype arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003, 308, 37-47.
41. Moreno, H.; Gallego, I.; Sevilla, N.; de la Torre, J.C.; Domingo, E.; Martín, V. Ribavirin can be mutagenic for arenaviruses. J. Virol. 2011, 85, 7246-7255.
42. Andrei, G.; de Clercq, E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antivir. Res. 1993, 22, 45-75.
43. Minakawa, N.; Takeda, T.; Sasaki, T.; Matsuda, A.; Ueda, T. Nucleotides and nucleosides. 96. Synthesis and antitumor activity of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. J. Med. Chem. 1991, 34, 778-786.
44. Sintchak, M.D.; Nimmesgern, E. The structure of inosine 5X-monophosphate dehydrogenase and the design of novel inhibitors. Inmunopharmacology 2000, 47, 163-184.
45. Goodell, J.R.; Madhok, A.A.; Hiasa, H.; Ferguson, D.M. Synthesis and evaluation of acridone-and acridone-based anti-herpes agents with topoisomerase activity. Bioorg. Med. Chem. 2006, 14, 5467-5480.
46. Lowden, C.T.; Bastow, K.F. Cell culture replication of herpes simplex virus and, or human cytomegalovirus is inhibited by 3,7-dialkoxylated, 1-hydroxyacridone derivatives. Antivir. Res. 2003, 59, 143-154.
47. Itoigawa, M.; Ito, C.; Wu, T.S.; Enjo, F.; Tokuda, H.; Nishino, H.; Furukawa, H. Cancer chemopreventive activity of acridone alkaloids on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Cancer Lett. 2003, 193, 133-138.
48. Zarubaev, V.V.; Slita, A.V.; Krivitskaya, V.Z.; Sirotkin, A.K.; Kovalenko, A.L.; Chatterjee, N.K. Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro. Antivir. Res. 2003, 58, 131-137.
49. Fujiwara, M.; Okamoto, M.; Okamoto, M.; Watanabe, M.; Machida, H.; Shigeta, S.; Konno, K.; Yokota, T.; Baba, M. Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells. Antivir. Res. 1999, 43, 179-189.
50. Turpin, J.A.; Buckheit, R.W., Jr.; Derse, D.; Hollingshead, M.; Williamson, K.; Palamone, C.; Osterling, M.C.; Hill, S.A.; Graham, L.; Schaeffer, C.A.; et al. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob. Agents Chemother. 1998, 42, 487-494.
51. Tabarrini, O.; Manfroni, G.; Fravolini, A.; Cecchetti, V.; Sabatini, S.; de Clercq, E.; Rozenski, J.; Canard, B.; Dutartre, H.; Paeshuyse, J.; et al. Synthesis and anti-BVDV activity of acridones as new potential antiviral agents. J. Med. Chem. 2006, 49, 2621-2627.
52. Manfroni, G.; Paeshuyse, J.; Massari, S.; Zanoli, S.; Gatto, B.; Maga, G.; Tabarrini, O.; Cecchetti, V.; Fravolini, A.; Neyts, J. Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: Identification of an NS3 helicase inhibitor. J. Med. Chem. 2009, 52, 3354-3365.
53. Stankiewicz-Drogon, A.; Dörner, B.; Erker, T.; Boguszewska-Chachulska, A.M. Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. J. Med. Chem. 2010, 53, 3117-3126.
54. Vispé, S.; Vandenberghe, I.; Robin, M.; Annereau, J.P.; Créancier, L.; Pique, V.; Galy, J.P.; Kruczynski, A.; Barret, J.M.; Bailly, C. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem. Pharmacol. 2007, 73, 1863-1872.
55. Watterson, S.H.; Chen, P.; Zhao, Y.; Gu, H.H.; Dhar, T.G.; Xiao, Z.; Ballentine, S.K.; Shen, Z.; Fleener, C.A.; Rouleau, K.A.; et al. Acridone-Based inhibitors of inosine 5'-monophosphate dehydrogenase: Discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl) pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroxyacridine-3-carboxamide (BMS-566419). J. Med. Chem. 2007, 50, 3730-3742.
56. Adams, A. Crystal structures of acridines complexed with nucleic acids. Curr. Med. Chem. 2002, 9, 1667-1675.
57. Sepúlveda, C.S.; Fascio, M.L.; Mazzucco, M.B.; Palacios, M.L.; Pellón, R.F.; García, C.C.; D'Accorso, N.B.; Damonte, E.B. Synthesis and evaluation of N-substituted acridones as antiviral agents against hemorrhagic fever viruses. Antivir. Chem. Chemother. 2008, 19, 41-47.
58. Gowen, B.B.; Wong, M.H.; Larson, D.; Ye, W.; Jung, K.H.; Sefing, E.J.; Skirpstunas, R.; Smee, D.F.; Morrey, J.D.; Schneller, S.W. Development of a new Tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS One 2010, 16, e12760.
59. Guillerm, G.; Guillerm, D.; Vandenplas-Vitkowski, C.; Glapski, C.; de Clercq, E. Inactivation of S-adenosyl-L-homocysteine hydrolase with novel 5'-thioadenosine derivatives. Antiviral effects. Bioorg. Med. Chem. Lett. 2003, 13, 1649-1652.
60. Venables, J.P.; Koh, C.S.; Froehlich, U.; Lapointe, E.; Couture, S.; Inkel, L.; Bramard, A.; Paquet, E.R.; Watier, V.; Durand, M.; et al. Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol. Cell Biol. 2008, 28, 6033-6043.
61. He, Y.; Smith, R. Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. Cell. Mol. Life Sci. 2009, 66, 1239-1256.
62. Han, S.P.; Tang, Y.H.; Smith, R. Functional diversity of the hnRNPs: Past, present and perspectives. Biochem. J. 2010, 430, 379-392.
63. Castilla, V.; Scolaro, L.A. Involvement of heterogeneous nuclear ribonucleoproteins in viral multiplication. Future Virol. 2012, 7, 575-591.
64. Katoh, H.; Mori, Y.; Kambara, H.; Abe, T.; Fukuhara, T.; Morita, E.; Moriishi, K.; Kamitani, W.; Matsuura, Y. Heterogeneous nuclear ribonucleoprotein A2 participates in the replication of Japanese encephalitis virus through an interaction with viral proteins and RNA. J. Virol. 2011, 85, 10976-10988.
65. Shih, S.R.; Stollar, V.; Li, M.L. Host factors in enterovirus 71 replication. J. Virol. 2011, 85, 9658-9666.
66. Monette, A.; Ajamian, L.; López-Lastra, M.; Mouland, A.J. Human immunodeficiency virus type 1 (HIV-1) induces the cytoplasmic retention of heterogeneous nuclear ribonucleoprotein A1 by disrupting nuclear import: Implications for HIV-1 gene expression. J. Biol. Chem. 2009, 284, 31350-31362.
67. Shabman, R.S.; Gulcicek, E.E.; Stone, K.L.; Basler, C.F. The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin α1 and partially alters its nuclear import. J. Infect. Dis. 2011, 204, S904-S910.
68. Jahrling, P.B.; Hesse, R.A.; Rhoderick, J.B.; Elwell, M.A.; Moe, J.B. Pathogenesis of a Pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 1981, 32, 872-880.
69. Bowick, G.C.; Spratt, H.M.; Hogg, A.E.; Endsley, J.J.; Wiktorowicz, J.E.; Kurosky, A.; Luxon, B.A.; Gorenstein, D.G.; Herzog, N.K. Analysis of the differential host cell nuclear proteome induced by attenuated and virulent hemorrhagic arenavirus infection. J. Virol. 2009, 83, 687-700.
70. Lukashevich, I.S.; Djavani, M.; Rodas, J.D.; Zapata, J.C.; Usborne, A.; Emerson, C.; Mitchen, J.; Jahrling, P.B.; Salvato, M.S. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J. Med. Virol. 2002, 67, 171-186.
71. Lukashevich, I.S.; Rodas, J.D.; Tikhonov, I.I.; Zapata, J.C.; Yang, Y.; Djavani, M.; Salvato, M.S. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch. Virol. 2004, 149, 2319-2336.
72. Djavani, M.M.; Crasta, O.R.; Zapata, J.C.; Fei, Z.; Folkerts, O.; Sobral, B.; Swindells, M.; Bryant, J.; Davis, H; Pauza, C.D.; et al. Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol. 2007, 81, 7960-7973.
73. Maeto, C.A.; Knott, M.E.; Linero, F.N.; Ellenberg, P.C.; Scolaro, L.A.; Castilla, V. Differential effect of acute and persistent Junin virus infections on the nucleo-cytoplasmic trafficking and expression of heterogeneous nuclear ribonucleoproteins type A and B. J. Gen. Virol. 2011, 92, 2181-2190.
74. Ellenberg, P.; Edreira, M.; Lozano, M.; Scolaro, L. Synthesis and expression of viral antigens in Vero cells persistently infected with Junin virus. Arch. Virol. 2002, 147, 1543-1557.
75. Ellenberg, P.; Edreira, M.; Scolaro, L. Resistance to superinfection of Vero cells persistently infected with Junin virus. Arch. Virol. 2004, 149, 507-522.
76. Keating, J.A.; Striker, R. Phosphorylation events during viral infections provide potential therapeutic targets. Rev. Med. Virol. 2012, 22, 166-181.
77. Dissmeyer, N.; Schnittger, A. The age of protein kinases. Methods Mol. Biol. 2011, 779, 7-52.
78. Buchkovich, N.J.; Yu, Y.; Zampieri, C.A.; Alwine, J.C. The TORrid affairs of viruses: Effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat. Rev. Microbiol. 2008, 6, 266-275.
79. Cooray, S. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J. Gen. Virol. 2004, 85, 1065-1076.
80. Ji, W.T.; Liu, H.J. PI3K-Akt signaling and viral infection. Recent. Pat. Biotechnol. 2008, 2, 218-226.
81. McCormick, F. Cancer: Survival pathways meet their end. Nature 2004, 428, 267-269.
82. Zhang, X.; Tang, N.; Hadden, T.J.; Rishi, A.K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 2011, 181, 31978-31986.
83. Linero, F.N.; Scolaro, L.A. Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro. Virus Res. 2009, 145, 166-170.
84. Radoshitzky, S.R.; Abraham, J.; Spiropoulou, C.F.; Kuhn, J.H.; Nguyen, D.; Li, W.; Nagel, J.; Schmidt, P.J.; Nunberg, J.H.; Andrews, N.C.; et al. Transferrin receptor 1 is a cellular receptor for New World hemorrhagic fever arenaviruses. Nature 2007, 446, 92-96.
85. Ruggiero, T.; Trabucchi, M.; Ponassi, M.; Corte, G.; Chen, C.Y.; al-Haj, L.; Khabar, K.S.; Briata, P.; Gherzi, R. Identification of a set of KSRP target transcripts upregulated by PI3K-AKT signaling. BMC Mol. Biol. 2007, 8, 28:1-28:15.
86. Cao, W.; Henry, M.D.; Borrow, P.; Yamada, H.; Elder, J.H.; Ravkov, E.V.; Nichol, S.T.; Compans, R.W.; Campbell, K.P.; Oldstone, M.B. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282, 2079-2081.
87. Pasqual, G.; Rojek, J.M.; Masin, M.; Chatton, J.Y.; Kunz, S. Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog. 2011, 7, e1002232.
88. Urata, S.; Ngo, N.; de la Torre, J.C. The PI3K/Akt pathway contributes to arenavirus budding. J. Virol. 2012, 86, 4578-4585.
89. Sullivan, J.A.; Kim, E.H.; Plisch, E.H.; Peng, S.L.; Suresh, M. FOXO3 regulates CD8 T cell memory by T cell-intrinsic mechanisms. PLoS Pathog. 2012, 8, e1002533.
90. Pleschka, S. RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol. Chem. 2008, 389, 1273-1282.
91. Vela, E.M.; Bowick, G.C.; Herzog, N.K.; Aronson, J.F. Genistein treatment of cells inhibits arenavirus infection. Antivir. Res. 2008, 77, 153-156.
92. Rojek, J.M.; Moraz, M.L.; Pythoud, C.; Rothenberger, S.; van der Goot, F.G.; Campbell, K.P.; Kunz, S. Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. Cell. Microbiol. 2012, 14, 1122-1134.
93. Vela, E.M.; Bowick, G.C.; Herzog, N.K.; Aronson, J.F. Exploring kinase inhibitors as therapies for human arenavirus Infections. Future Virol. 2008, 3, 243-251.
94. Castilla, V.; Merisch, S. Low pH-induced fusion of Vero cells infected with Junin virus. Arch. Virol.1996, 141, 1307-1317.
95. Di Simone, C.; Zandonatti, M.; Buchmeier, M. Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology 1994, 198, 455-465.
96. Di Simone, C.; Buchmeier, M. Kinetics and pH dependence of acid-induced structural changes in the Lymphoytic choriomeningitis virus glycoprotein complex. Virology 1995, 209, 3-9.
97. Borrow, P.; Oldstone, M.B. Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology 1994, 198, 1-9.
98. Shah, W.A.; Peng, H.; Carbonetto, S. Role of non-raft cholesterol in lymphocytic choriomeningitis virus infection via {alpha}-dystroglycan. J. Gen. Virol. 2006, 87, 673-678.
99. Quirin, K.; Eschli, B.; Scheu, I.; Poort, L.; Kartenbeck, J.; Helenius, A. Lymphocytic choriomeningitis virus uses a novel endocytic pathway for infectious entry via late endosomes. Virology 2008, 378, 21-33.
100. Rojek, J.M.; Perez, M.; Kunz, S. Cellular entry of lymphocytic choriomeningitis virus. J. Virol. 2008, 82, 1505-1517.
101. Rojek, J.M.; Sanchez, A.B.; Nguyen, N.T.; de la Torre, J.C.; Kunz, S. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J. Virol. 2008, 82, 7677-7687.
102. Martinez, M.G.; Cordo, S.M.; Candurra, N.A. Characterization of JUNV arenavirus cell entry. J. Gen. Virol. 2007, 88, 1776-1784.
103. Vela, E.M.; Colpitts, T.M.; Zhang, L.; Davey, R.A.; Aronson, J.F. Pichinde virus is trafficked through a dynamin 2 endocytic pathway that is dependent on cellular Rab5-and Rab7-mediated endosomes. Arch. Virol. 2008, 153, 1391-1396.
104. Martínez, M.G.; Forlenza, M.B.; Candurra, N.A. Involvement of cellular proteins in Junin arenavirus entry. Martinez MG, Forlenza MB, Candurra NA. Biotechnol. J. 2009, 4, 866-870.
105. Lee, A.M.; Pasquato, A.; Kunz, S. Novel approaches in anti-arenaviral drug development. Virology 2011, 411, 163-169.
106. Kolokoltsov, A.A.; Adhikary, S.; Garver, J.; Johnson, L.; Davey, R.A.; Vela, E.M. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Arch. Virol. 2012, 157, 121-712.
107. Thomsen, A.R.; Nansen, A.; Andreasen, S.O.; Wodarz, D.; Christensen, J.P. Host factors influencing viral persistence. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2000, 355, 1031-1041.
108. Zuniga, E.I.; Hahm, B.; Oldstone, M.B. Type I interferon during viral infections: Multiple triggers for a multifunctional mediator. Curr. Top. Microbiol. Immunol. 2007, 316, 337-357.
109. Borrow, P.; Martínez-Sobrido, L.; de la Torre, J.C. Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses 2010, 2, 2443-2480.
110. Cuevas, C.D.; Lavanya, M.; Wang, E.; Ross, S.R. Junin virus infects mouse cells and induces innate immune responses. J. Virol. 2011, 85, 11058-11068.
111. Baize, S.; Pannetier, D.; Faure, C.; Marianneau, P.; Marendat, I.; Georges-Courbot, M.C.; Deubel, V. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 2006, 8, 1194-1202.
112. Martínez-Sobrido, L.; Zúñiga, E.I.; Rosario, D.; García-Sastre, A.; de la Torre, J.C. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2006, 80, 9192-9199.
113. Martínez-Sobrido, L.; Giannakas, P.; Cubitt, B.; García-Sastre, A.; de la Torre, J.C. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 2007, 81, 12696-12703.
114. Pythoud, C.; Rodrigo, W.W.; Pasqual, G.; Rothenberger, S.; Martínez-Sobrido, L.; de la Torre, J.C.; Kunz, S. Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKK{varepsilon}. J. Virol. 2012, 86, 7728-7738.
115. Rodrigo, W.W.; Ortiz-Riaño, E.; Pythoud, C.; Kunz, S.; de la Torre, J.C.; Martínez-Sobrido, L. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J. Virol. 2012, 86, 8185-8197.
116. Fan, L.; Briese, T.; Lipkin, W.I. Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction. J. Virol. 2010, 84, 1785-1791.
117. Pindel, A.; Sadler, A. The role of protein kinase R in the interferon response. J. Interferon Cytokine Res. 2011, 31, 59-70.
118. Montero, H.; Trujillo-Alonso, V. Stress granules in the viral replication cycle. Viruses 2011, 3, 2328-2338.
119. Linero, F.N.; Thomas, M.G.; Boccaccio, G.L.; Scolaro, L.A. Junin virus infection impairs stress-granule formation in Vero cells treated with arsenite via inhibition of eIF2 alpha phosphorylation. J. Gen. Virol. 2011, 92, 2889-2899.
120. Brostrom, C.O.; Prostko, C.R.; Kaufman, R.J.; Brostrom, M.A. Inhibition of translational initiation by activators of the glucose-regulated stress protein and heat shock protein stress response systems. Role of the interferon-inducible double-stranded RNA-activated eukaryotic initiation factor alpha kinase. J. Biol. Chem. 1996, 271, 24995-25002.
121. Cuevas, C.D.; Lavanya, M.; Wang, E.; Ross, S.R. Junin virus infects mouse cells and induces innate immune responses. J Virol. 2011, 85, 11058-11068.
122. Oliveira-Nascimento, L.; Massari, P.; Wetzler, L.M. The Role of TLR2 in Infection and Immunity. Front. Immunol. 2012, 3, 79.
123. Zhou, S.; Kurt-Jones, E.A.; Mandell, L.; Cerny, A.; Chan, M.; Golenbock, D.T.; Finberg, R.W. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 2005, 35, 822-830.
124. Zhou, S.; Halle, A.; Kurt-Jones, E.A.; Cerny, A.M.; Porpiglia, E.; Rogers, M.; Golenbock, D.T.; Finberg, R.W. Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses. J. Neuroimmunol. 2008, 194, 70-82.
125. Zhou, S.; Cerny, A.M.; Bowen, G.; Chan, M.; Knipe, D.M.; Kurt-Jones, E.A.; Finberg, R.W. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. Antivir. Res. 2010, 87, 295-306.
126. Hayes, M.W.; Carrion, R., Jr.; Nunneley, J.; Medvedev, A.E.; Salvato, M.S.; Lukashevich, I.S. Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro. J. Virol. 2012, 86, 7216-7226.
127. Bieniasz, P.D. Intrinsic immunity: A front-line defense against viral attack. Nat. Immunol. 2004, 5, 1109-1115.
128. Tavalai, N.; Stamminger, T. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta. 2008, 1783, 2207-2221.
129. Wolf, D.; Goff, S.P. Host restriction factors blocking retroviral replication. Annu. Rev. Genet. 2008, 42, 143-163.
130. Hinson, E.R.; Joshi, N.S.; Chen, J.H.; Rahner, C.; Jung, Y.W.; Wang, X.; Kaech, S.M.; Cresswell, P. Viperin is highly induced in neutrophils and macrophages during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 2010, 184, 5723-5731.
131. Sakuma, T.; Sakurai, A.; Yasuda, J. Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses. PLoS One 2009, 4, e6934.
132. Radoshitzky, S.R.; Dong, L.; Chi, X.; Clester, J.C.; Retterer, C.; Spurgers, K.; Kuhn, J.H.; Sandwick, S.; Ruthel, G.; Kota, K.; et al. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 2010, 84, 10569-10580.
133. Everett, R.D.; Chelbi-Alix, M.K. PML and PML nuclear bodies: Implications in antiviral defence. Biochimie 2007, 89, 819-830.
134. Bernardi, R.; Pandolfi, P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 2007, 8, 1006-1016.
135. Borden, K.L.; Culjkovic, B. Perspectives in PML: A unifying framework for PML function. Front. Biosci. 2009, 14, 497-509.
136. Lang, M.; Jegou, T.; Chung, I.; Richter, K.; Münch, S.; Udvarhelyi, A.; Cremer, C.; Hemmerich, P.; Engelhardt, J.; Hell, S.W.; et al. Three-Dimensional organization of promyelocytic leukemia nuclear bodies. J. Cell Sci. 2010, 123, 392-400.
137. Dyck, J.A.; Maul, G.G.; Miller, W.H., Jr.; Chen, J.D.; Kakizuka, A.; Evans, R.M. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994, 76, 333-343.
138. Lavau, C.; Marchio, A.; Fagioli, M.; Jansen, J.; Falini, B.; Lebon, P.; Grosveld, F.; Pandolfi, P.P.; Pelicci, P.G.; Dejean, A. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995, 11, 871-876.
139. Chee, A.V.; Lopez, P.; Pandolfi, P.P.; Roizman, B. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol 2003, 77, 7101-7105.
140. Regad, T.; Chelbi-Alix, M.K. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001, 20, 7274-7286.
141. Borden, K.L.; Campbell Dwyer, E.J.; Salvato, M.S. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J. Virol. 1998, 72, 758-766.
142. García, C.C.; Topisirovic, I.; Djavani, M.; Borden, K.L.; Damonte, E.B.; Salvato, M.S. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem. Biophys. Res. Commun. 2010 393, 625-630.
143. Borden, K.L.; Campbell Dwyer, E.J.; Salvato, M.S. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. FEBS Lett. 1997, 418, 30-34.
144. Djavani, M.; Rodas, J.; Lukashevich, I.S.; Horejsh, D.; Pandolfi, P.P.; Borden, K.L.; Salvato, M.S. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J. Virol. 2001, 75, 6204-6208.
145. Bonilla, W.V.; Pinschewer, D.D.; Klenerman, P.; Rousson, V.; Gaboli, M.; Pandolfi, P.P.; Zinkernagel, R.M.; Salvato, M.S.; Hengartner, H. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 2002, 76, 3810-3818.
146. El McHichi, B.; Regad, T.; Maroui, M.A.; Rodriguez, M.S.; Aminev, A.; Gerbaud, S.; Escriou, N.; Dianoux, L.; Chelbi-Alix, M.K. SUMOylation promotes PML degradation during encephalomyocarditis virus infection. J. Virol. 2010, 84, 11634-11645.